PDX model details
| PDX ID |
386R |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Renal |
Current Generation (* indicates number of generations grown in Castrate host) |
12 |
| Average PDX Generation Time (days +/- SEM) |
135 ± 10 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
386R |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
Y |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 386R |
PIK3CB |
0.500503 |
2.82941 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
PIK3CA |
1.91339 |
7.53386 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
CHD7 |
0.490041 |
2.80897 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
MYC |
0.490041 |
2.80897 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
MLH1 |
-0.755716 |
1.1845 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
CTNNB1 |
-0.755716 |
1.1845 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
SETD2 |
-0.755716 |
1.1845 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
CDH1 |
-0.760688 |
1.18043 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
ZFHX3 |
-0.760688 |
1.18043 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
FANCA |
-0.760688 |
1.18043 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
| 386R |
TP53 |
-0.769771 |
1.17302 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted GARVAN Panel |
hg19 |
Clinical Information
| Sample Number |
386R |
| Sample Site |
Prostate |
| Sample source |
Radical prostatectomy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
9 |
| Primary Gleason Score |
4 |
| Secondary Gleason Score |
5 |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
5 |
| Tumour Grade |
pT3bN1 |
| D'Amico Risk Classification |
7 |
| Tumour Volume (in cc) |
36.0 |
| Treatment Prior to Specimen Collection |
None |
| |
|
Patient Information
| Patient Number |
386 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
6.98 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 386R |
ZNF717 |
10 |
1.0 |
stop_gained |
'5/5 |
. |
23.7 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 386R |
ZNF717 |
10 |
1.0 |
stop_gained |
'5/5 |
. |
23.7 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 386R |
FANCD2 |
344 |
0.77 |
missense_variant |
'16/43 |
4.06E-06 |
27.8 |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 386R |
TP53 |
679 |
0.7 |
frameshift_variant |
'10/11 |
. |
. |
-
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 386R |
GATA2 |
1326 |
0.66 |
missense_variant |
'6/6 |
4.48E-05 |
28.6 |
Uncertain_significance
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 386R |
APC |
549 |
0.49 |
missense_variant |
'16/16 |
. |
26.2 |
Conflicting_interpretations_of_pathogenicity
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
| 386R |
APC |
666 |
0.48 |
missense_variant |
'16/16 |
0.0002035 |
23.3 |
Conflicting_interpretations_of_pathogenicity
|
Targeted GARVAN Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
Illumina HiSeq 2500 |
No information in Drug dosing Table